A study from the Department of Cancer Biology, Dana-Farber Cancer Institute; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA; and others shows that “Cyclin D1–Cdk4 controls glucose metabolism independently of cell cycle progression.”
This study was published in the June 26, 2014 Nature [I.F >42] by Prof. Puigserver and others from the Department of Cancer Biology, Dana-Farber Cancer Institute; Department of Cell Biology, Harvard Medical School, Boston, Massachusetts, USA.
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: Molecular therapy for DM: Upregulator of cell proliferation inhibits gluconeogenesis and hyperglycemia via up regulation of Cyclin D1. Thus, pharmacological formulations encompassing “Upregulator of cell proliferation activators“ may be used in the treatment of DM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., Molecular therapy for DM: Upregulator of cell proliferation inhibits gluconeogenesis and hyperglycemia via up regulation of Cyclin D1, 29/April/2015, 13.35, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
Undisclosed information: How Upregulator of cell proliferation increases the expression of CyclinD1
* Research cooperation
